Systems pharmacology in drug discovery and therapeutic insight for herbal medicines

Briefings in Bioinformatics

Volumn 15, Issue 5, 2013, Pages 710-733

  Huang, Chao ^a   Zheng, Chunli ^b   Li, Yan ^c   Wang, Yonghua ^a   Lu, Aiping ^d   Yang, Ling ^e  

^a NORTHWEST A F UNIVERSITY   (China)

^b NORTHWEST UNIVERSITY   (China)

^c DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^d HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^e DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

ADME; Depression; Herbal medicines; Network pharmacology; Systems pharmacology

Indexed keywords

DRUG DEVELOPMENT; HERBAL MEDICINE; PHARMACOKINETICS; PHARMACOLOGY;

DRUG DISCOVERY; HERBAL MEDICINE; PHARMACOKINETICS; PHARMACOLOGY;

EID: 84887495304     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbt035     Document Type: Article

References (146)

1. Cheung F. TCM: made in China. Nature 2011;480:S82-S83.
2. Xu X. New concepts and approaches for drug discovery based on traditional Chinese medicine. Drug DiscovToday Technol 2006;3:247-253.
3. He S-M, Chan E, Zhou S-F. ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr PharmDes 2011;17:357-407.
4. Van der Greef J. Perspective: all systems go. Nature 2011; 480:S87-S87.
5. Lehár J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009;27:659-666.
6. Tian P. Convergence: where west meets east. Nature 2011; 480:S84-S86.
7. Su X, Kong L, Lei X, et al. Biological fingerprinting analysis of traditional Chinese medicines with targeting ADME/ Tox property for screening of bioactive compounds by chromatographic and MS methods. Mini Rev Med Chem 2007;7:87-98.
8. Van de Waterbeemd H, Gifford E. ADMET in silico modelling:towards prediction paradise? Nat Rev Drug Discov 2003;2:192-204.
9. Boobis A, Gundert-Remy U, Kremers P, et al. In silico prediction of ADME and pharmacokinetics: Report of an expert meeting organised by COST B15. Eur J Pharm Sci 2002;17:183-193.
10. Li X, Xu X, Wang J, et al. A system-level investigation into the mechanisms of Chinese traditional medicine: compound danshen formula for cardiovascular disease treatment. PLoS One 2012;7:e43918.
11. Tao W, Xu X, Wang X, et al. Network pharmacologybased prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol 2012;145:1-10.
12. Ekins S, Waller CL, Swaan PW, et al. Progress in predicting human ADME parameters in silico. JPharmacolToxicolMethods 2000;44:251-272.
13. Castillo-Garit JA, Marrero-Ponce Y, Torrens F, et al. Estimation of ADME properties in drug discovery:Predicting Caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices. J Pharm Sci 2008;97:1946-1976.
14. Delie F, Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit RevTher Drug Carrier Syst 1997;14:221.
15. Anderle P, Niederer E, Rubas W, et al. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci 1998;87:757-762.
16. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. AdvDrugDeliv Rev 2001;46:27-43.
17. Yu H, Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug DiscovToday 2003;8:852-861.
18. Lennernas H, Ahrenstedt Ö, Ungell A. Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. BrJClin Pharmacol 1994;37:589-596.
19. Wang J, Hou T. Recent advances on in silico ADME modeling. Annu Rep Comput Chem 2009;5:101-127.
20. Segall M, Beresford A. Virtual ADME-Tox: the Promise of Technology in Pre-Clinical Development. London: Enabling Technologies: Delivering the Future for Pharmaceutical R&D, PJP Publications Ltd., 2002;93-110.
21. Stoner CL, Troutman M, Gao H, et al. Moving in silico screening into practice: A minimalist approach to guide permeability screening. LettDrug DesDiscov 2006;3:575-581.
22. Jung E, Kim J, Kim M, et al. Artificial neural network models for prediction of intestinal permeability of oligopeptides. BMC Bioinformatics 2007;8:245.
23. Guangli M, Yiyu C. Predicting Caco-2 permeability using support vector machine and chemistry development kit. J Pharm Pharm Sci 2006;9:210-221.
24. Liu R, So S-S. Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 1. Aqueous solubility. J Chem Inform Comput Sci 2001;41:1633-1639.
25. Chen Y, Zhu Q-J, Pan J, et al. A prediction model for blood-brain barrier permeation and analysis on its parameter biologically. Comput Methods Programs Biomed 2009;95:280-287.
26. Abraham MH, Ibrahim A, Zhao Y, et al. A data base for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data. J Pharm Sci 2006;95:2091-2100.
27. Zhang L, Zhu H, Oprea TI, et al. QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm Res 2008;25:1902-1914.
28. Norinder U, Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev 2002;54:291-313.
29. Mehdipour AR, Hamidi M. Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug DiscovToday 2009;14:1030-1036.
30. Cardoso FL, Brites D, Brito MA. Looking at the blood- brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev 2010;64:328-363.
31. Pokalwar RU, Shinde PV, Chidrawar AB, et al. Chemistry and biology interface. Chem Biol 2012;2:31-37.
32. Wang Z, Chen Y, Liang H, et al. P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J Chem InformModel 2011;51:1447-1456.
33. Xue Y, Yap CW, Sun L, et al. Prediction of P-glycoprotein substrates by a support vector machine approach. J Chem Inform Comput Sci 2004;44:1497-1505.
34. Wang Y-H, Li Y, Yang S-L, et al. An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network. J Comput Aided Mol Des 2005;19:137-147.
35. Li Q, Fang Y, Li X, et al. Mechanism of the plant cytochrome P450 for herbicide resistance: a modelling study. J Enzyme InhibMed Chem 2012;1-10.
36. Ai C, Li Y, Wang Y, et al. Investigation of binding features:effects on the interaction between CYP2A6 and inhibitors. JComputChem 2010;31:1822-1831.
37. Wang Y, Li Y, Wang B. An in silico method for screening nicotine derivatives as cytochrome P450 2A6 selective inhibitors based on kernel partial least squares. Int J Mol Sci 2007;8:166-179.
38. Wang Y, Li Y, Li Y, et al. Modeling Km values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. Bioorg Med Chem Lett 2005;15:4076-4084.
39. Cariello NF, Wilson JD, Britt BH, et al. Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity. Mutagenesis 2002;17:321-329.
40. D'yachkov P, Kharchevnikova N, Dmitriev A, et al. Quantum chemical simulation of cytochrome P450 catalyzed aromatic oxidation: metabolism, toxicity, and biodegradation of benzene derivatives. Int J Quantum Chem 2007; 107:2454-2478.
41. Ekins S, Bravi G, Binkley S, et al. Three and four dimensional- quantitative structure activity relationship (3D/4DQSAR) analyses of CYP2D6 inhibitors. Pharmacogenet Genomics 1999;9:477-489.
42. Czodrowski P, Kriegl JM, Scheuerer S, et al. Computational approaches to predict drug metabolism. Expert Opin Drug MetabToxicol 2009;5:15-27.
43. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. DrugMetab Rev 2003;35:35-98.
44. Pleuvry BJ. Modes of drug elimination. Anaesth Intensive CareMed 2005;6:277-279.
45. Yang L, Liu H, Ma H, et al. Application of systems biology to absorption, distribution, metabolism and excretion in Traditional Chinese Medicine. World Sci Tech ModernTrad ChinMed 2007;9:98-104.
46. Wang X, Xu X, Li Y, et al. Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication. Integ Biol 2013;5:351-371.
47. Wang X, Xu X, Tao W, et al. A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease. Evid Based ComplementAlternatMed 2012;2012:519031.
48. Liu H, Wang J, Zhou W, et al. Systems approaches and polypharmacology for drug discovery from herbal medicines:an example using Licorice. J Ethnopharmacol 2013; 146:773-793.
49. Kuruvilla FG, Shamji AF, Sternson SM, et al. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 2002;416:653-657.
50. Jensen LJ, Saric J, Bork P. Literature mining for the biologist:from information retrieval to biological discovery. Nat Rev Genet 2006;7:119-129.
51. Özgür A, Vu T, Erkan G, et al. Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics 2008;24:i277-i285.
52. Pospisil P, Iyer LK, Adelstein SJ, et al. A combined approach to data mining of textual and structured data to identify cancer-related targets. BMC Bioinformatics 2006;7:354.
53. Ye H, Ye L, Kang H, et al. HIT: linking herbal active ingredients to targets. Nucleic Acids Res 2011;39:D1055-D1059.
54. Liu X, Ouyang S, Yu B, et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res 2010;38:W609-W614.
55. Hao M, Li Y, Wang Y, et al. A classification study of human b 3-adrenergic receptor agonists using BCUT descriptors. Mol Divers 2011;15:877-887.
56. Yu H, Chen J, Xu X, et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 2012;7:e37608.
57. Zhou W, Huang C, Li Y, et al. A systematic identification of multiple toxin-target interactions based on chemical, genomic and toxicological data. Toxicology 2013;304:173-184.
58. Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25:197-206.
59. Cai J, Han C, Hu T, et al. Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation. Protein Sci 2006;15:2071-2081.
60. Chen Y, Zhi D. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001;43:217-226.
61. Paul N, Kellenberger E, Bret G, et al. Recovering the true targets of specific ligands by virtual screening of the protein data bank. Proteins 2004;54:671-680.
62. Li B, Xu X, Wang X, et al. A systems biology approach to understanding the mechanisms of action of Chinese herbs for treatment of cardiovascular disease. IntJMol Sci 2012;13:13501-13520.
63. Chen X, Ji Z, Chen YZ. TTD: therapeutic target database. Nucleic Acids Res 2002;30:412-415.
64. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011;39:D1035-D1041.
65. Traditional Chinese Medicine Systems Pharmacology Database. http://tcmspnw.com/login_clearSession (October 30, 2012, date last accessed.)
66. Chen CY-C. TCM Database@ Taiwan: the world's largest Traditional Chinese Medicine database for drug screening in silico. PLoS One 2011;6:e15939.
67. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-690.
68. Allen JA, Roth BL. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev PharmacolToxicol 2011;51:117-144.
69. Mestres J, Gregori-Puigjané E, Valverde S, et al. Data completeness- the Achilles heel of drug-target networks. Nat Biotechnol 2008;26:983-984.
70. Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Ann Rev PharmacolToxicol 2012;52:505-521.
71. Liu R, Hu J. Computational prediction of heme-binding residues by exploiting residue interaction network. PLoS One 2011;6:e25560.
72. Yu H, Kim PM, Sprecher E, et al. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007;3:e59.
73. Emilie M, Hafner-Burton MK. Network analysis for international relations. IntOrg 2009;63:559-592.
74. Daigle BJJr, Srinivasan BS, Flannick JA, et al. Current progress in static and dynamic modeling of biological networks. Syst Biol SignalNetw 2010;1:13-73.
75. Zhou W, Li Y, Wang X, et al. MiR-206-mediated dynamic mechanism of the mammalian circadian clock. BMC Syst Biol 2011;5:141.
76. Guthke R, Möller U, Hoffmann M, et al. Dynamic network reconstruction from gene expression data applied to immune response during bacterial infection. Bioinformatics 2005;21:1626-1634.
77. Padulles J, Ault G, McDonald J. An integrated SOFC plant dynamic model for power systems simulation. JPowerSources 2000;86:495-500.
78. Wang Y, Li Y, Wang B. Stochastic simulations of the cytochrome P450 catalytic cycle. J Phys Chem B 2007;111:4251-4260.
79. Lamboni M, Makowski D, Lehuger S, et al. Multivariate global sensitivity analysis for dynamic crop models. Field Crops Res 2009;113:312-320.
80. Kitano H. Systems biology: a brief overview. Science 2002; 295:1662-1664.
81. Hidalgo CA, Blumm N, Barabási A-L, et al. A dynamic network approach for the study of human phenotypes. PLoSComput Biol 2009;5:e1000353.
82. Strazzullo P, D'Elia L, Kandala N-B, et al. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BrMedJ 2009;339:b4567.
83. Werner E. All systems go. Nature 2007;446:493-494.
84. Murray B, Fortinberry A, Statistics D, et al. 'Depression facts and stats'. http://www.upliftprogram.com/depression_stats. html#recovery2005 (22 May 2013, date last accessed).
85. Clancy CM, Cronin K. Evidence-based decision making:global evidence, local decisions. Health Affairs 2005;24:151-162.
86. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004;4:227-235.
87. Tavazoie S, Hughes JD, Campbell MJ, et al. Systematic determination of genetic network architecture. Nat Genet 1999;22:281-285.
88. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 2006;45:449-468.
89. Xu X, Zhang W, Huang C, et al. A novel chemometric method for the prediction of human oral bioavailability. IntJMol Sci 2012;13:6964-6982.
90. Li L, Li Y, Wang Y, et al. Prediction of human intestinal absorption based on molecular indices. J Mol Sci 2007;23:286-291.
91. Li L, Li Y,Wang Y, et al. Prediction of BBB permeation based on molecular indices. ChinJMedChem 2007;17:221-228.
92. Gharge D, Pavan T, Sunil B, et al. Hyperforin as a natural antidepressant: an overview. JPharmRes 2009;2:1373-1375.
93. Hokkanen J, Tolonen A, Mattila S, et al. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci 2011;42:273-284.
94. Hosseinzadeh H, Motamedshariaty V, Hadizadeh F. Antidepressant effect of kaempferol, a constituent of saffron (Crocus sativus) petal, in mice and rats. Pharmacologyonline 2007;2:367-370.
95. Butterweck V, Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien MedWochenschr 2007;157:356-361.
96. Isacchi B, Galeotti N, Bergonzi M, et al. Pharmacological in vivo test to evaluate the bioavailability of some St John's Wort innovative oral preparations. Phytother Res 2009;23:197-205.
97. Kubin A, Wierrani F, Burner U, et al. Hypericin-the facts about a controversial agent. Curr Pharm Des 2005;11:233-253.
98. Mukherjee PK, Ponnusankar S, Venkatesh P, et al. Synergy in herbal medicinal products: concept to realization. Ind J Pharm EducRes 2011;45:210-217.
99. Butterweck V, Hegger M, Winterhoff H. Flavonoids of St. John's Wort reduce HPA axis function in the rat. Planta Med 2004;70:1008-1011.
100. Shoji N, Umeyama A, Saito N, et al. Asimilobine and lirinidine, serotonergic receptor antagonists, from Nelumbo nucifera. JNat Prod 1987;50:773-774.
101. Protais P, Arbaoui J, Bakkali E-H, et al. Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod 1995;58:1475-1484.
102. Iovieno N, Dalton ED, Fava M, et al. Second-tier natural antidepressants: review and critique. J Affect Disord 2011; 130:343-357.
103. Panossian A, Nikoyan N, Ohanyan N, et al. Comparative study of Rhodiola preparations on behavioral despair of rats. Phytomedicine 2008;15:84-91.
104. Priest R, Gimbrett R, Roberts M, et al. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatr Scand 1995;91:40-43.
105. Van Diermen D, Marston A, Bravo J, et al. Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol 2009;122:397-401.
106. Wu CH, Apweiler R, Bairoch A, et al. The Universal Protein Resource (UniProt): an expanding universe of protein information. NucleicAcidsRes 2006;34:D187-D191.
107. Altman RB. PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet 2007;39:426.
108. Davis AP, Murphy CG, Johnson R, et al. The comparative toxicogenomics Database: update 2013. Nucleic Acids Res 2013;41:D1104-D1114.
109. Carney RM, Freedland KE, Sheline YI, et al. Depression and coronary heart disease: a review for cardiologists. Clin Cardiol 1997;20:196-200.
110. Haug TT, Mykletun A, Dahl A. Are anxiety and depression related to gastrointestinal symptoms in the general population? ScandJGastroenterol 2002;37:294-298.
111. Wilson I. Depression in the patient with COPD. IntJChron Obstruct Pulmon Dis 2006;1:61-64.
112. Leikin JB. Substance-related disorders in adults. DisMonth 2007;53:313-335.
113. Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002;26:941-962.
114. Shi Y, Zhi X, Zheng H, et al. Rapid cloning and functional characterization of hypericin synthase gene. Acta Pharm Sin 2012;47:670-676.
115. Müller N, Schwarz M, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. MolPsychiatry 2006;11:680-684.
116. Müller N. COX-2 inhibitors as antidepressants and antipsychotics:clinical evidence. CurrOpin InvestigDrugs 2010; 11:31-42.
117. Muller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008;14:1452-1465.
118. Serretti A, Chiesa A, Calati R, et al. No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. Psychiatry Res 2011;188:166-169.
119. Shu H-J, Eisenman LN, Jinadasa D, et al. Slow actions of neuroactive steroids at GABAA receptors. J Neurosci 2004; 24:6667-6675.
120. Berridge MJ, Taylor C. 'Inositol trisphosphate and calcium signaling'. Cold Spring Harb Symp Quant Biol 1988;53:927-933.
121. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the'' hedonic'' dopamine synapse. J Neurol Neurosurg Psychiatry 1989;52:724-731.
122. Carvalho A, Caldeira M, Santos S, et al. Role of the brainderived neurotrophic factor at glutamatergic synapses. BrJ Pharmacol 2008;153:S310-S324.
123. Groc L, Gustafsson B, Hanse E. AMPA signalling in nascent glutamatergic synapses: there and not there!. Trends Neurosci 2006;29:132-139.
124. Rozov A, Burnashev N. Polyamine-dependent facilitation of postsynaptic AMPA receptors counteracts paired-pulse depression. Nature 1999;401:594-598.
125. Sangkuhl K, Klein T, Altman R. Selective serotonin reuptake inhibitors (SSRI) pathway. Pharmacogenet Genomics 2009;19:907-909.
126. Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 2010;11:501-505.
127. Whirl-Carrillo M, McDonagh E, Hebert J, et al. Pharmacogenomics knowledge for personalized medicine. Clin PharmacolTher 2012;92:414-417.
128. Voleti B, Duman R. The roles of neurotrophic factor and wnt signaling in depression. Clin PharmacolTher 2011;91:333-338.
129. McKernan DP, Dinan TG, Cryan JF. 'Killing the Blues': a role for cellular suicide (apoptosis) in depression and the antidepressant response? ProgNeurobiol 2009;88:246-263.
130. Bader GD, Betel D, Hogue CW. BIND: the biomolecular interaction network database. Nucleic Acids Res 2003;31:248-250.
131. Stark C, Breitkreutz B-J, Reguly T, et al. BioGRID: a general repository for interaction datasets. Nucleic Acids Res 2006;34:D535-D539.
132. Salwinski L, Miller CS, Smith AJ, et al. The database of interacting proteins: 2004 update. Nucleic Acids Res 2004; 32:D449-D451.
133. Peri S, Navarro JD, Amanchy R, et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 2003;13:2363-2371.
134. Aranda B, Achuthan P, Alam-Faruque Y, et al. The IntAct molecular interaction database in 2010. Nucleic Acids Res 2010;38:D525-D531.
135. Zanzoni A, Montecchi-Palazzi L, Quondam M, et al. MINT: a molecular interaction database. FEBS Lett 2002; 513:135-140.
136. Pagel P, Kovac S, Oesterheld M, et al. The MIPS mammalian protein-protein interaction database. Bioinformatics 2005;21:832-834.
137. Beuming T, Skrabanek L, Niv MY, et al. PDZBase: a protein- protein interaction database for PDZ-domains. Bioinformatics 2005;21:827-828.
138. Vastrik I, D'Eustachio P, Schmidt E, et al. Reactome: a knowledge base of biologic pathways and processes. Genome Biol 2007;8:R39.
139. Sun Y, Zhu R, Ye H, et al. Towards a bioinformatics analysis of anti-Alzheimer's herbal medicines from a target network perspective. Brief Bioinformatics 2013;14:327-43.
140. Zhao Y, Zhang W, Kho Y, et al. Proteomic analysis of integral plasma membrane proteins. Anal Chem 2004;76:1817-1823.
141. David Y, Lih-Chi C, Yuh-Chiang S, et al. Protein kinase A-dependent neuronal nitric oxide synthase activation mediates the enhancement of baroreflex response by adrenomedullin in the nucleus tractus solitarii of rats. J Biomed Sci 2011;18:32-40.
142. Zhou QG, Hu Y, Hua Y, et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 2007;103:1843-1854.
143. Künzel HE, Zobel AW, Nickel T, et al. Treatment of depression with the CRH-1-receptor antagonist R121919:endocrine changes and side effects. J Psychiatr Res 2003;37:525-533.
144. Kohl P, Crampin E, Quinn T, et al. Systems biology: an approach. Clin PharmacolTher 2010;88:25-33.
145. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009;25:2466-2472.
146. Arrell D, Terzic A. Network systems biology for drug discovery. Clin PharmacolTher 2010;88:120-125.